OptMAVEn-2.0: De novo Design of Variable Antibody Regions Against Targeted Antigen Epitopes
Monoclonal antibodies are becoming increasingly important therapeutic agents for the treatment of cancers, infectious diseases, and autoimmune disorders. However, laboratory-based methods of developing therapeutic monoclonal antibodies (e.g., immunized mice, hybridomas, and phage display) are time-c...
Main Authors: | Ratul Chowdhury, Matthew F. Allan, Costas D. Maranas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4468/7/3/23 |
Similar Items
-
OptMAVEn-2.0: De novo Design of Variable Antibody Regions Against Targeted Antigen Epitopes
by: Chowdhury, Ratul, et al.
Published: (2018) -
OptMAVEn--a new framework for the de novo design of antibody variable region models targeting specific antigen epitopes.
by: Tong Li, et al.
Published: (2014-01-01) -
Concerns with computational protein engineering programmes IPRO and OptMAVEn and metabolic pathway engineering programme optStoic
by: Thomas K. Wood
Published: (2021-02-01) -
Computationally-driven identification of antibody epitopes
by: Casey K Hua, et al.
Published: (2017-12-01) -
Characterizing Epitope Binding Regions of Entire Antibody Panels by Combining Experimental and Computational Analysis of Antibody: Antigen Binding Competition
by: Benjamin D. Brooks, et al.
Published: (2020-08-01)